Kaempferol inhibited VEGF and PGF expression and in vitro angiogenesis of hrecs under diabetic-like environment

Brazilian Journal of Medical and Biological Research

Volumn 50, Issue 3, 2017, Pages

  Xu, X H ^a,b   Zhao, C ^a   Peng, Q ^b   Xie, P ^a   Liu, Q H ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Liberation Army   (China)

Author keywords

Anti angiogenic; Diabetic retinopathy; Kaempferol; PGF; VEGF

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; GLUCOSE; KAEMPFEROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; VASCULOTROPIN; KAEMPFEROL DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; ONCOGENE SRC; REAL TIME POLYMERASE CHAIN REACTION; RETINAL ENDOTHELIAL CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; RETINA;

CELL MOVEMENT; CELL PROLIFERATION; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; KAEMPFEROLS; PLACENTA GROWTH FACTOR; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85014734224     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20165396     Document Type: Article

References (29)

1. Hampton BM, Schwartz SG, Brantley MA Jr, Flynn HW Jr. Update on genetics and diabetic retinopathy. Clin Ophthalmol 2015; 9: 2175–2193.
2. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis 2015; 2: 17, doi: 10.1186/s40662-015-0026-2.
3. Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res 2015; 99: 137–148, doi: 10.1016/j.phrs.2015.05.013.
4. Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O’Neal DN, Januszewski AS. Biomarkers in diabetic retinopathy. Rev Diabet Stud 2015; 12: 159–195, doi: 10.1900/RDS. 2015.12.159.
5. Li JK, Wei F, Jin XH, Dai YM, Cui HS, Li YM. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab. Int J Ophthalmol 2015; 8: 1202–1206.
6. Jiang Q, Zhao F, Liu X, Li R, Liu J. Effect of miR-200b on retinal endothelial cell function under high glucose environment. Int J Clin Exp Pathol 2015; 8: 10482–10487.
7. Gong CY, Lu B, Hu QW, Ji LL. Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor. Int J Ophthalmol 2013; 6: 573–577.
8. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991; 88: 9267–9271, doi: 10.1073/pnas. 88.20.9267.
9. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44: 1–9, doi: 10.3858/emm.2012.44.1.025.
10. Tjwa M, Luttun A, Autiero M, Carmeliet P. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 2003; 314: 5–14, doi: 10.1007/s00441-003-0776-3.
11. Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, McLeod D, et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 1998; 78: 109–116.
12. Calderon-Montano JM, Burgos-Moron E, Perez-Guerrero C, Lopez-Lazaro M. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 2011; 11: 298–344, doi: 10.2174/138955711795305335.
13. Kim SH, Choi KC. Anti-cancer effect and underlying mechanism(s) of kaempferol, a phytoestrogen, on the regulation of apoptosis in diverse cancer cell models. Toxicol Res 2013; 29: 229–234, doi: 10.5487/TR.2013.29.4.229.
14. Sak K. Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev 2014; 8: 122–146, doi: 10.4103/0973-7847.134247.
15. Luo H, Rankin GO, Juliano N, Jiang BH, Chen YC. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFkappaB-cMyc-p21 pathway. Food Chem 2012; 130: 321–328, doi: 10.1016/j.foodchem. 2011.07.045.
16. Liang F, Han Y, Gao H, Xin S, Chen S, Wang N, et al. Kaempferol identified by zebrafish assay and fine fractiona-tions strategy from Dysosma versipellis Inhibits angiogenesis through VEGF and FGF pathways. Sci Rep 2015; 5: 14468, doi: 10.1038/srep14468.
17. Kowluru RA, Kowluru A, Mishra M, Kumar B. Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res 2015; 48: 40–61, doi: 10.1016/j.preteyeres.2015.05.001.
18. Nabavi SF, Habtemariam S, Daglia M, Shafighi N, Barber AJ, Nabavi SM. Anthocyanins as a potential therapy for diabetic retinopathy. Curr Med Chem 2015; 22: 51–58, doi: 10.2174/0929867321666140815123852.
19. Mahoney SE, Loprinzi PD. Influence of flavonoid-rich fruit and vegetable intake on diabetic retinopathy and diabetes-related biomarkers. J Diabetes Complications 2014; 28: 767–771, doi: 10.1016/j.jdiacomp.2014.06.011.
20. Saric A, Balog T, Sobocanec S, Kusic B, Sverko V, Rusak G, et al. Antioxidant effects of flavonoid from Croatian Cystus incanus L. rich bee pollen. Food Chem Toxicol 2009; 47: 547–554, doi: 10.1016/j.fct.2008.12.007.
21. Devi KP, Malar DS, Nabavi SF, Sureda A, Xiao J, Nabavi SM, et al. Kaempferol and inflammation: From chemistry to medicine. Pharmacol Res 2015; 99: 1–10, doi: 10.1016/j.phrs.2015.05.002.
22. Medinger M, Halter J, Heim D, Buser A, Gerull S, Stern M, et al. Angiogenic markers in plasma cell myeloma patients treated with novel agents. Anticancer Res 2015; 35: 1085–1090.
23. Marcellini M, De Luca N, Riccioni T, Ciucci A, Orecchia A, Lacal PM, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 2006; 169: 643–654, doi: 10.2353/ajpath.2006. 051041.
24. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH, Chen YC. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer 2009; 61: 554–563, doi: 10.1080/01635580802666281.
25. Wang J, Fang F, Huang Z, Wang Y, Wong C. Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist. FEBS Lett 2009; 583: 643–647, doi: 10.1016/j.febslet.2009.01.030.
26. Zhang K, Lu J, Mori T, Smith-Powell L, Synold TW, Chen S, et al. Baicalin increases VEGF expression and angiogenesis by activating the ERR(alpha)/PGC-1(alpha) pathway. Cardiovasc Res 2011; 89: 426–435, doi: 10.1093/cvr/cvq296.
27. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237–268.
28. Huang Q, Sheibani N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/ Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol 2008; 295: C1647–C1657, doi: 10.1152/ajpcell.00322.2008.
29. Xin X, Khan ZA, Chen S, Chakrabarti S. Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis. Lab Invest 2004; 84: 1451–1459, doi: 10.1038/labinvest.3700178.